Skip to main content
PLOS One logoLink to PLOS One
. 2023 Dec 21;18(12):e0295441. doi: 10.1371/journal.pone.0295441

Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells

Risa Mia Swain 1,2, Anahi Sanchez 1, Denisse A Gutierrez 1, Armando Varela-Ramirez 1, Renato J Aguilera 1,*
Editor: Wagdy Mohamed Eldehna3
PMCID: PMC10734950  PMID: 38127921

Abstract

In an effort to identify novel anti-cancer agents, we employed a well-established High Throughput Screening (HTS) assay to assess the cytotoxic effect of compounds within the ChemBridge DIVERSet Library on a lymphoma cell line. This screen revealed a novel thiophene, F8 (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl) amino]-3-thiophenecarboxylate), that displays anti-cancer activity on lymphoma, leukemia, and other cancer cell lines. Thiophenes and thiophene derivatives have emerged as an important class of heterocyclic compounds that have displayed favorable drug characteristics. They have been previously reported to exhibit a broad spectrum of properties and varied uses in the field of medicine. In addition, they have proven to be effective drugs in various disease scenarios. They contain anti-inflammatory, anti-anxiety, anti-psychotic, anti-microbial, anti-fungal, estrogen receptor modulating, anti-mitotic, kinase inhibiting and anti-cancer activities, rendering compounds with a thiophene a subject of significant interest in the scientific community. Compound F8 consistently induced cell death at a low micromolar range on a small panel of cancer cell lines after a 48 h period. Further investigation revealed that F8 induced phosphatidylserine externalization, reactive oxygen species generation, mitochondrial depolarization, kinase inhibition, and induces apoptosis. These findings demonstrate that F8 has promising anti-cancer activity.

Introduction

As cancer disparities increase as the years go by, it has become an urgent requirement for scientists to find alternative approaches to cancer treatment. It is projected that by the end of the year 2023, 59,610 new cases of leukemia will be diagnosed, and 23,710 people will die from the disease in the U.S. [1]. The overall leukemia incidence rate has increased by 1% annually in children since 1975 [1]. Cancer can be linked to evading normal apoptotic mechanisms and causing dysregulated proliferation of cancer cells [2]. Investigation of important biological pathways that play a role in apoptosis, may aid in understanding where the dysregulation occurs. New targeted chemotherapy agents are being explored and used to kill cancer cells specifically [3,4]. Many compounds in regular clinical use have displayed versatile applicability, some of which include anti-cancer activity.

After screening 1300 compounds, a novel thiophene compound was found to elicit potent cytotoxicity on the Acute Lymphoblastic Leukemia (ALL) CCRF-CEM cell line using the Differential Nuclear Staining (DNS) assay [9]. Thiophene is a heteroaromatic compound comprising of a five membered ring, with a sulfur atom located at the first position. Thiophene and its derivatives, with various substituents, constitute a significant group of heterocyclic compounds that are greatly important in medical chemistry, showcasing a range of intriguing applications [5]. Compounds containing a thiophene have exhibited diverse therapeutic properties, including anti-inflammatory, anti-psychotic, anti-anxiety, kinase inhibiting, and most importantly anti-cancer effects [5]. In the U.S. and Canada, thiophenes and their derivatives have demonstrated efficacy in treating diverse cancers and other clinical diseases [6,7]. For example, 2- Butylthiophene, a well-known thiophene has been used in the process of synthesizing anti-cancer agents. A serotonin agonist used in the treatment of Alzheimer’s is derived from a maleate salt containing a thiophene, 1-(2,5-dimethylthiophen-3-yl)-3-(5-methyl-1H-imidazol-4-yl)propan-1-one [5]. These versatile compounds show promising activity, and here we will explore thiophene carboxylate F8 (Fig 1) anti-cancer activity in vitro. This study revealed that compound F8 exhibited cytotoxic effects on various human cancer cell lines. We examined this compound on a relatively sensitive cells, the Acute Lymphoblastic Lymphoma, CCRF-CEM cell line, to determine the likely cause of cytotoxicity and the mode of action this novel compound uses to induce cell death.

Fig 1. Chemical structure of F8 (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl)amino]-3-thiophenecarboxylate).

Fig 1

Materials and methods

Cell lines and culture conditions

F8 cytotoxicity was evaluated on seven human cancer and one non-cancerous human cell line. All utilized cell lines used in this study were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Cell lines of blood cancer origin: CCRF-CEM (Acute Lymphoblastic Leukemia, ATCC CRL-2265), Jurkat (Acute Lymphoblastic Leukemia, ATCC CRL-2899), and NALM6 (Acute Lymphoblastic Leukemia, ATCC CRL-3273) were cultured with complete culture medium using RPMI-1640 (Hyclone, Logan UT, USA), with 10% fetal bovine serum (FBS, Hyclone), 100 μg/mL penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific Inc. Rockford, IL). Of the cell lines of blood cancer origin, HL-60 (promyeloblast, ATCC CCL-240) required a 20% FBS in their culture media. In addition, a triple-negative breast adenocarcinoma cell line MDA-MB-231 (ATCC CRM-HTB-26), PANC-1 (ATCC CRL-1469), and A-375 (ATCC CRL-1619) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, CORNING, Corning, NY). DMEM medium was supplemented with 10% FBS and 100 U/mL penicillin, and 100 μg/mL streptomycin. Non-tumorigenic foreskin fibroblast cells, Hs-27 (ATCC CR-1634), were also cultured in a complete DMEM medium. Consistently, all cells were cultured in a 5% CO2 humidified 37°C incubator.

Prior to the use of the cell lines for the following experiments, the viability was assessed via flow cytometry using propidium iodide (P.I.) [8]. Cell populations with a 95% viability or higher were seeded into a multi-well plate.

Preparation of compound

The experimental compound was sourced from the ChemBridge DIVERset library (ChemBridge Corporation, San Diego, CA) and was pre-diluted to 10 mM in dimethyl sulfoxide (DMSO). The compound (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl) amino]-3-thiophenecarboxylate), also known as F8, was found in said library set and used for the experiments detailed below. Aliquots and other concentrations of F8 were thawed and diluted with DMSO. The positive control, H2O2, was diluted in 1 x phosphate-buffered saline (PBS).

Compound screening analysis

Thirteen hundred compounds were screened from the ChemBridge DIVERset library using the CCRF-CEM cell line. The primary screening was at a concentration of 10 μM by differential nuclear staining assay (Z’ = 0.86) [9]. Upon screening, compounds that induced >50% cell death were subjected to a secondary screening to determine the 50% of cytotoxic concentration (CC50) value. In the secondary screening, we used concentrations ranging from 0.01 μM to 30 μM to determine the concentration of the experimental compound required to disrupt 50% of the cell population [10].

Differential nuclear staining to determine CC50

The cytotoxicity compound F8 was assessed on the CCRF-CEM cell line through a DNS live-cell bioimaging assay [9]. CCRF-CEM cells were seeded in 96-well plates at a density of 10,000 cells per well, each containing 100 μl of tissue culture medium. Subsequently, the cells were then treated with a gradient of concentrations (0.01 μM to 5 μM) with compound F8 for a 48 h time point. The cells were plated with the compound itself, a solvent control (dimethyl sulfide; 1% DMSO; Millipore Sigma, St. Louis, MO USA), a positive control 1 mM hydrogen peroxide (H202; Millipore Sigma, St. Louis, MO USA), and untreated cells for reference. To distinguish between both live and dead cells, each well received propidium iodide (P.I.; Biotium; Fremont, CA, USA) and Hoescht 33,342 (Invitrogen; Eugene, OR, USA) at a concentration of 5 μg/ml for each dye, with a 2 h incubation at 37°C. Hoechst is a fluorescent dye that permeates both live and dead cells, whereas P.I. selectivity can only permeate cells whose plasma membrane is compromised. Images were captured from each well using a 96 multi-well plate reader ImageXpress Pico automated cell imaging system (Molecular Devices; San Jose, CA). The cytotoxic concentrations were determined as previously described [9] using a linear interpolator calculator available at (https://www.johndcook.com/interpolator.html).

Phosphatidylserine externalization

One of the well-known first indicators of apoptosis is the translocation of phosphatidylserine (PS) on the cell surface [11,12]. We sought to determine the mechanism of death that compound F8 induces in CCRF-CEM cells. Flow cytometry provides a convenient method for detection of phosphatidylserine (PS) through the conjugation of Annexin V-FITC, a member of a protein family that binds to the negatively charged phospholipids, serving as a marker for cells when PS translocates to the cell surface. In this study, CCRF-CEM cells were initially seeded in a 24-well plate at 100,000 cell density, each well containing1 mL of media. The cells were then incubated overnight with F8 CC50 (obtained after 24 h incubation) and 2X CC50 (2.89 μM and 5.78 μM). For the controls, DMSO was used for the vehicle control; as a positive control, cells were treated with 1 mM H2O2, and untreated cells were used to evaluate the baseline of the dead cell population, acting as a negative control for cytotoxicity.

Following treatment, the cells were then collected and placed on flow tubes on ice. They were then washed with ice-cold PBS and centrifuged at 1200 RPM for 5 min. The resulting pellets were then resuspended in Annexin V-FITC and P.I. in 100 μl of binding buffer and incubated in the dark on ice for 15 min. Ice-cold binding buffer (400 μl) was then added before the analyses and read immediately by the flow cytometer. Approximately 10,000 events/cells were acquired per sample by using the Kaluza software (Backman Coulter), and samples were done in triplicates. The total apoptotic cell populations were determined by combining both the early and late stages of apoptosis [19]. We conducted three separate measurements and calculated the average and standard deviation, resulting in the determination of the percentages of both apoptotic and necrotic cells.

Assessing mitochondrial membrane potential

To assess the integrity of the mitochondrial membrane in CCRF-CEM cells following exposure to F8, we employed the MitoProbe JC-1 Assay Kit from Molecular Probes (M34152). The fluorescent cationic probe (5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide JC-1) is able accumulate inside the mitochondria. In mitochondria where the membrane is intact, the JC-1 dye will aggregate and emit red fluorescent complexes. In mitochondria with a damaged membrane, the JC-1 dye cannot accumulate and form aggregates, staying as monomers that emit green fluorescence [13,14]. This red/green fluorescence serves as a dependable indicator of mitochondrial integrity. In this assay, CCRF-CEM cells were first seeded in a 24-well plate in 1mL complete culture media at a density of 100,000 cells per well. The cells were then subjected to treatment with F8 24 h CC50 and 2X CC50 (2.89 μM and 5.78 μM). The controls for this assay are the same as previously described, and each sample was run in three independent measurements. Following incubation, the cells were gathered, centrifuged at 1200 RPM, and resuspended in 500 μl of PBS containing 2 μM of JC-1 dye. Following this, the cells were then incubated at 37°C for 30 min and then washed with warm PBS prior to analyses. When examined in the flow cytometer, cells emitting only a green fluorescence signal (~529 nm) indicate mitochondrial depolarization (damage). In contrast, cells emitting a red fluorescent signal (~590 nm) indicate that their mitochondria are polarized and in a healthy state.

Reactive oxygen species accumulation

Reactive oxygen species (ROS) in the cell produce oxidative stress in the mitochondria by retrograde redox signaling [15]. The generation of reactive oxygen species can serve as an indicator of mitochondrial dysfunction in the intrinsic apoptotic pathway [16]. To assess the levels of ROS in CCRF-CEM cells, we utilized the 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) reagent (Invitrogen, C400) [15]. Intracellular esterase’s cleave this nonfluorescent carboxy-H2DCFDA leading to oxidation and forming a green fluorescent product 2′,7′-dichlorofluorescein (DCF) [17]. The cells were seeded in a 24-well plate in 1 mL of complete media, at a density of 100,000 cells per well and treated with F8 24 h CC50 and 2X CC50 (2.89 μM and 5.78 μM) with the same controls as previously mentioned for an 18 h incubation. As previously mentioned, the experimental and control treatments were evaluated in three independent measurements and normalized. Post incubation, the samples were collected and centrifuged at 1200 RPM for 5 min. Afterward, they were resuspended in a pre-warmed mixture of carboxy-H2DCFDA and 1 x PBS, making a final concentration of 10 μM dye. Cells were then incubated for 1 h at 37°C, followed by another centrifugation for 1200 RPM for 5 min. Following resuspension in 500 μl PBS, the cells were given a 30 min recovery period and then analyzed by the flow cytometer.

Caspase 3/7 activation

Upon initiation of apoptosis, caspase 3/7 are activated to proceed with the process of apoptosis. The activation of caspase 3/7 within the cells was evaluated by using a cell membrane permeable fluorogenic NucView 488 caspase substrate [18]. By permeating living cells with an intact membrane, the substrate is able to be cleaved. This process forms a high-affinity DNA dye that stains the nucleus green [19]. CCRF-CEM cells were treated with F8 24 h CC50 and 2X CC50 (2.89 μM and 5.78 μM) for 8 h. The cells were harvested and centrifuged at 1200 RPM for 5 min. The pellets were resuspended in 200 μl of PBS containing 5 μl of NucView488 caspase 3/7 substrate. This mixture was then incubated in the dark at room temperature for 45 min. Following the incubation, 300 μl of PBS was added to each flow tube and read immediately via a flow cytometer. In the flow cytometer, a green fluorescent signal indicates that caspase 3/7 activation is occurring within the cell. Each sample was performed in three independent measurements utilizing the Kaluza software (Beckman Coulter).

Cell cycle analysis

To investigate F8 ability to induce alteration in cell cycle profile, CCRF-CEM cells were plated in 24-well plates at a density of 100,000 cells per well, with each well containing1 ml of media [20]. CCRF-CEM cells were treated with F8 CC25 and CC10 (1.44 μM and 0.57 μM obtained after 24 h) for 72 h. The controls that were used for this assay are the same as described above. After the 72 h incubation, the cells were harvested in flow cytometry tubes and centrifuged at 1200 RPM for 5 min. The cells were then resuspended in 100 μl of room temperature media. The nuclear isolation medium (NIM)-DAPI reagent was resuspended in each flow tube (200 μl) and analyzed via flow cytometry. The NIM-DAPI dye can stain the cell nuclei, aiding in quantifying the total amount of DNA per cell. As previously stated, the samples were run in three independent measurements, and 10,000 events per sample were acquired (Gallios; Kaluza software; Beckman Coulter).

MAPK and JAK-STAT array

To gage the phosphorylation of essential biological pathways sometimes responsible for oncogenesis, a MAPK and JAK-STAT Array was conducted (RayBiotech Human/Mouse MAPK Phosphorylation Array AAH-MAPK-1-2, Human JAK-STAT Pathway Phosphorylation Array C1 AAH-JAK-STAT-1-2). This experiment utilized the CCRF-CEM cell line. The cells were treated with 2X CC50 (5.78 μM) of F8 and DMSO as vehicle control for 4 h. The cells were then harvested in 15 ml conical tubes, pelleted, and transferred to 1.5 ml tubes. The cells were then washed with 1 ml of PBS and pelleted again by centrifugation at 1000 g for 6 min. Following the centrifugation, the PBS was removed, and the pellet was resuspended in the 1X working solution of the Cell Lysis Buffer containing Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail. The cells were rocked gently at 4°C for 1 h. The total protein extracts were then transferred to microcentrifuge tubes and centrifuged for 1200 RPM for 10 min. The protein concentrations were determined utilizing a bicinchoninic acid (BCA) assay for total protein concentration (Thermo Scientific Pierce Rapid Gold BCA Protein Assay Kit, A53225). Protein lysates were stored for later use.

Membranes for the MAPK and JAK-STAT were blocked using 2 ml of blocking buffer for 30 min at room temperature. The blocking buffer was then removed, and 1 ml of the undiluted sample was put into each well with the membranes and incubated overnight at 4°C. Following the overnight incubation, the samples were aspirated from each well and washed with washer buffer I for 5 min at room temperature; this wash was repeated 3 times. The membranes were washed with washer buffer II for 5 min at room temperature; this step was performed 2 times. One ml of the prepared detection antibody cocktail was pipetted into each well and incubated overnight at 4°C. The membrane was then washed in the same manner as previously mentioned, and 2 ml of 1X HRP-Anti-Rabbit IgG was pipetted into each well and incubated for 2 hours. The HRP-Anti-Rabbit IgG was pipetted from each well and washed in the same manner. The membranes were then transferred to blotting paper to remove any excess washer buffer and placed printed side up onto a plastic sheet lying on a flat surface. The detection buffer mixture was added onto each membrane and incubated for 2 min at room temperature. Another plastic sheet was placed on top of the membranes and gently rolled across in order to smooth out air bubbles. The sandwich membranes were then read via the Thermo Fisher iBright for chemiluminescence imaging. Densitometry was obtained using the Thermo Fisher iBright Densitometry analysis software. The data was then normalized per the manufacturer’s recommendation.

Statistical analyses

Each data point within the experiment was derived from a minimum of three separate measurements. A total of eight independent measurements were utilized to determine the overall cell count in the samples treated with the vehicle in the conducted DNS assays. To calculate the 50% cytotoxic concentration (CC50), we utilized linear interpolation as previously described. Statistical significance was established by computing P-values using a two-tailed paired Student’s t-test to compare the vehicle-treated and experimental groups, using the t-test or the 2 independent Means software accessible at (https://www.socscistatistics.com/tests/studenttest/default2.aspx). Significant P-values, indicated by asterisks, are as follows: * P<0.05, ** P<0.01, and *** P<0.001.

Results

Detection of cell death via the differential nuclear staining (DNS) assay

The cytotoxic effect of F8 was analyzed using the Differential Nuclear Staining imaging assay on seven human cancer cell lines and one non-cancerous fibroblast cell line. The DNS assay, which has a robust Z’ factor of 0.86, was utilized because it is reliable and validated for primary and secondary screenings for potential cytotoxic compounds [9,10]. Hoechst fluorescent dye is able to permeate both living and dead cells when exposed for 2 h before reading, providing the total number of cells [21]. In contrast, P.I. selectively permeates cells whose membrane has been compromised, thus labeling only dead cells. As indicated in Table 1, F8 displays a gradient of cytotoxicity across various human cancer cells tested. All grown cell lines were incubated at 48 h with F8 to obtain their CC50 value. The adherent cell lines, A373, PANC-1, MDA-MB-231, and Hs-27, were initially left to incubate overnight to allow their attachment to the bottom of the plate in media. This is done solely in the absence of the compound so the cells can properly adhere. Lastly, a concentration gradient of F8 in triplicate was added to the cells. After an extra 48 h incubation, a dose-response curve was generated for calculating the concentration at which 50% (CC50) of the cell population have died. The values depicted in the Table 1 range from 0.856 μM on CEM to 29.41 μM on the Hs-27 cell line. The data suggest potential selectivity in leukemia and lymphoma cell lines, with the CC50 being at or below 1 μM to the adherent cell lines whose CC50 is above 1 μM. In this study, we continued our experiments in the CCRF-CEM cell line to partially elucidate the mechanism of action of F8.

Table 1. Cytotoxicity values of F8.

Cell Type Cell Line CC50 μM Mean ± S.D. SCI*
Acute Lymphoblastic Lymphoma CCRF-CEM 0.856 0.356 34.35
Acute T Cell Leukemia JURKAT 0.805 0.021 36.53
Acute Promyelocytic Leukemia HL-60 1.29 0.356 22.79
Pancreatic Carcinoma PANC-1 1.48 0.07 19.87
Malignant Melanoma A375 2.69 0.40 10.93
Breast Adenocarcinoma MDA-MB-231 3.05 0.32 9.64
Normal Foreskin Epithelial Hs-27 29.41 0.127 -

Determination of the 50% cytotoxic concentration (CC50) and Selective Cytotoxic Index (SCI) on multiple cancer cell lines at a 48 h time point.

*SCI index values were calculated using the following equation: CC50 of non-cancerous cells (Hs-27 fibroblasts) divided by the CC50 of the cancer cell line.

F8-induced phosphatidylserine externalization in CCRF-CEM cells

To determine whether F8 causes death via apoptosis or necrosis, the detection of phosphatidylserine (P.S.) externalization was conducted in F8-treated CCRF-CEM cells. For this purpose, the Annexin V-FITC and propidium iodide (P.I.) assay and a flow cytometry protocol was utilized [9]. Moreover, we used the CC50 and twice (2X) the CC50 concentrations that were determined on CCRF-CEM. The data revealed that there is significant P.S. externalization compared to the DMSO-treated (solvent control) CCRF-CEM cells. As expected, there was a high percentage of P.S. externalization in the cells treated with the positive control H2O2, whereas the cells that were untreated or treated with the vehicle showed low P.S. externalization (Fig 2). The results indicate that F8 initiated apoptosis to signal for cell death due to the significant P.S. externalization in CCRF-CEM cells.

Fig 2. F8’s induction of apoptosis.

Fig 2

F8 compound-induced apoptosis in CEM cells. F8 ability to induce apoptosis was assessed in a phosphatidylserine externalization assay and measured through flow cytometry. Analysis was performed following a 24 h incubation with 24 h CC50 and 2X CC50 (2.89 μM and 5.78 μM). Controls included DMSO as the vehicle, H2O2 as the positive, and untreated. Significant phosphatidylserine externalization was evident for the CC50 and 2X CC50, given the p-value p<0.00001 (***).

F8 caused mitochondrial membrane depolarization

High levels of ROS can depolarize the mitochondria and cause damage to DNA, proteins, and lipids [22,23]. Many conditions that induce oxidative stress on the mitochondria evoke apoptosis [23]. We evaluated the effect of F8 on CCRF-CEM to detect mitochondrial depolarization using the JC-1reagent and flow cytometry. Cells were incubated for 4 h with CC50 (obtained after 24 h of incubation), and two times (2X) the CC50 (2.89 μM and 5.78 μM), and the integrity of the mitochondria was assessed. These analyses revealed the F8 induced significant depolarization to the cell’s mitochondria at the CC50 and 2X CC50 concentration compared to the vehicle control (Fig 3). Thus, F8 was able to depolarize the mitochondria in CCRF-CEM cells.

Fig 3. Depolarization of the mitochondria.

Fig 3

Significant mitochondrial depolarization was induced by compound F8 on CEM cells following a 4 h incubation treated with the CC50 and 2X CC50 (2.89 μM and 5.78 μM). The cells were stained with JC-1 reagent and analyzed by flow cytometry. Statistical analyses were obtained through the two-tailed Students paired t-test. The controls that were included are the same as previously stated.

Induction of ROS by F8 treatment

ROS generation indicates a disturbance in homeostasis, and their accumulation promotes apoptosis [24]. ROS accumulation was identified with carboxy-H2DCFDA reagent and analyzed by flow cytometry. To examine the accumulation of ROS, we treated CCRF-CEM cells with F8 CC50 and 2X CC50 (2.89 μM and 5.78 μM) and incubated them for 18 h. Significant ROS accumulation in F8-treated cells was evident (p = 0.0005, p = 0.003; Fig 4), suggesting the contribution of oxygen radicals to apoptosis.

Fig 4. F8 induced ROS accumulation.

Fig 4

Significant ROS was induced by F8 CC50 and 2X CC50 (2.89 μM and 5.78 μM) in CCRF-CEM cells compared to the vehicle control, DMSO, following an 18 h incubation period. Statistical analyses were acquired using a two-tailed t-test, p = 0.0005 and p = 0.003.

Activation of executioner caspases 3/7

Caspases play a crucial role in both triggering and carrying out the process of apoptosis. Caspases can be categorized into three groups, initiator caspases (caspases 2, 8, 9, and 10), executioner caspases (caspases 3, 6, and 7), and lastly, inflammatory caspases (1, 4, 5, 11, and 12) [25]. Caspase activity begins upon activation, and this is followed by nucleic acid cleavage. To affirm that F8 induces apoptosis, the activation of caspase 3/7 was measured in CCRF-CEM cells by flow cytometry. The cells were treated with CC50 and 2X CC50 (2.89 μM and 5.78 μM) and incubated for 8 h. Increased caspase was observed at the CC50 and 2X CC50 concentration and compared to the DMSO control (Fig 5). The confirmation of Caspase 3/7 activation indicated that F8 initiated the intrinsic apoptotic pathway as its mechanism of action.

Fig 5. F8 induces caspase activation.

Fig 5

Compound F8 CC50 and 2X CC50 (2.89 μM and 5.78 μM) induced significant caspase 3/7 activation in CEM cells. The cells were incubated for 8 h and stained with NucView 488 caspase-3/7 substrate. Statistical analyses were obtained using the two-tailed Student’s paired t-test compared to the vehicle control (1% DMSO).

F8 causes DNA fragmentation

To assess the effect F8 has on the cell cycle profile, the distribution of phases was evaluated on CCRF-CEM cells. The cells were treated with CC25 and CC10 (1.44 μM and 0.57 μM) for 72 h. It is important to note that at the 24 h CC50 concentration, extensive damage was observed and interfered with the cell cycle analyses, and for this reason, lower concentrations were used to observe cell cycle progression. The same controls were used in this experiment as those presented in the above sections. Although no significant changes in cell cycle progression were observed after F8 treatment, the induction of DNA fragmentation by F8 was demonstrated by an increase in the sub G0-G1 phase (Fig 6). The p-values of DMSO-treated cells compared with the experimental treatments were p = 0.007 and p = 0.027, respectively. In conclusion, DNA fragmentation was evident upon the treatment of F8 on the CCRF-CEM cell line after 72 hours.

Fig 6. F8 induced DNA fragmentation on CEM cells, a hallmark of apoptosis.

Fig 6

F8 cytotoxicity was analyzed via flow cytometer after a 72 h exposure on CEM cells utilizing CC25 and CC10 (1.44 μM and 0.57 μM). NIM-DAPI was used to stain each cell’s DNA amount and quantified in the flow. F8 displays DNA fragmentation evident in the Sub G0-G1 phase. Controls were included, DMSO as the vehicle and H2O2 as the positive control, and untreated cells, respectively.

F8-induced hypophosphorylation of critical biological enzymes

The phosphorylation of the MAPK and JAK-STAT were assessed on CEM cells with compound F8 with the use of the Human Phosphorylation Pathway Profiling Array C55. Cells were plated at a density of 2.7 x 106 per mL and treated with F8 2X CC50. Lysates of the vehicle (DMSO) and experimental samples were obtained and used for the membranes. Following exposure, the data was obtained via densitometry and normalized according to the protocol data analysis. As shown in Fig 7, signal reduction was observed for JAK-STAT from F8-treated cells compared to the DMSO-treated cells. The fold reduction for JAK1 was 0.74 in comparison to 1 for DMSO. The fold changes for JAK and STAT are as follows: JAK 2 (0.69), STAT 2 (0.64), STAT 3 (0.66), STAT 5 (0.69), STAT 6 (0.58), and TYK-2 (0.57). Interestingly, F8-treatment did not affect STAT 1 (0.86) and phosphorylation. The impact of JAK-STAT signaling on cancer cell survival, proliferation, invasion of tumors, coupled with the hyperactivation of STAT3 and STAT5; has positioned the JAK-STAT pathway as a potential pathway for cancer therapy [26]. Given the data, there was a reduction in the JAK and STAT pathways suggesting the compound may be inhibiting an essential biological pathway responsible for tumor progression. In addition to the JAK-STAT pathway, there was a reduction in the fold phosphorylation of other important regulators, most noticeably of the SHP Protein Tyrosine Phosphatase proteins SHP 1 (0.39) and SHP 2 (0.68) that would be predicted to reduce phosphatase activity. There was also a minor reduction in phosphorylation of the proto-oncogene SRC tyrosine-protein kinase (0.9) and a slight decrease in the phosphorylation of Epidermal Growth Factor Receptor (EGFR 0.76).

Fig 7. F8 causes hypophosphorylation in JAK/STAT pathway.

Fig 7

Human Phosphorylation Kinase Array C55 was conducted on the CCRF-CEM cell line and treated with 2X CC50 (5.78 μM). This assay was used to determine the phosphorylation status of MAPK and JAK-STAT membranes to gauge phosphorylation. Fold changes were determined using densitometry. Hyperphosphorylation was observed in the MAPK membrane versus the JAK-STAT. Hypophosphorylation was displayed in the JAK 1–2 and STAT 2–5.

In contrast, there were minor phosphorylation effects on MAP Kinase array proteins after F8-treatment, with values for ERK 1/2 (1.16), MSK2 (1.03), CREB (0.83), HSP 27 (0.94), JNK (1.04), MEK (0.94), MMK3 (0.82), MMK6 (0.94), P38 (1.10), P53 (0.73), and RSK 1 (1.18).

Our results indicate that F8 can downregulate members of the Jak/Stat pathway, suggesting a possible mechanism for induction of cell death.

Discussion

Previously it has been shown that thiophene compounds can induce apoptosis in cancer cell lines [27]. In the U.S., thiophenes have been utilized for the treatment of various cancers and other medical conditions [28]. Thiophenes are a sulfur-containing heterocyclic compounds that bind with a wide range of cancer-specific protein targets, depending on its nature [28]. Here we discuss the effects of thiophenecarboxylate compound, F8, and its ability to induce cell death in multiple cancer cell lines. F8 was found to cause cytotoxicity with CC50 values ranging from nanomolar to low micromolar concentrations (0.805 μM to 3.05 μM). Additionally, we demonstrated the compounds’ ability to induce apoptosis in the CCRF-CEM cell line by investigating phosphatidylserine externalization, the generation of reactive oxygen species, assessing the mitochondria’s membrane potential, and the activation of executioner caspase-3/7. Based on these assays, it was concluded that F8 induced cell death via the apoptotic pathway.

A cell in the process of apoptosis can follow through either the intrinsic or extrinsic pathway [29]. The intrinsic pathway involves the release of several factors via the mitochondria within the cell [30]. We performed a mitochondrial depolarization assay (JC-1) to assess the integrity of the mitochondria, an indication observed during apoptosis triggered through the intrinsic apoptotic pathway. Compound F8 induced significant depolarization of the mitochondria, thus proving F8 acts via the intrinsic apoptotic pathway.

We studied ROS generation in F8-treated CCRF-CEM cells. ROS generation is critical because it induces the depolarization of the mitochondria’s membrane [31]. Excessive generation of ROS can induce cellular stress, activates caspases, and ultimately results in cell death [32]. As shown in Fig 4, F8 induced ROS overproduction in CEM cells, thus leading to apoptosis.

By permeabilization of the mitochondrial membrane, the apoptotic executioner caspase-3 becomes activated [30]. Typically, an apoptotic death is irreversible after caspase-3 is activated [33]. Upon activation, caspases demolish key proteins and activate other enzymes. Caspase-3/7 activation was assessed in CCRF-CEM following treatment with F8. Significant caspase-3/7 activation was shown thus confirming that apoptosis was activated via the intrinsic pathway as part of the machinery used by F8 to inflict cell dead.

A cell cycle analysis measured cellular DNA content in CCRF-CEM cells upon treatment with F8. Interestingly, treatment with F8 did not induce significant change to the cell cycle profile in the CCRF-CEM cell line but caused DNA fragmentation. Cells in the process of apoptosis demonstrate a distinct morphological trait, DNA fragmentation, thus confirming our outcomes. [34].

A phosphorylation (activation) array was performed using thiophene F8-treated CCRF-CEM cell samples. We sought to determine if F8 can inhibit phosphorylation in the MAPK, JAK, STAT, and ERK pathways since thiophenes have been previously shown to inhibit the phosphorylation of essential biological pathways [27]

Our results indicate that JAK 1 and JAK 2 were hypophosphorylated after F8 treatment. The JAK-STAT pathway, a significant route in cancer development, consolidates signals from diverse cytokines, hormones, and growth factors to either activate or suppress gene expression.[35]. It’s been shown that the persistent activation of JAK 2 and STAT 3 found in many different cancers play essential roles in the development of malignancies [26]. Hyperactivation of JAK 2 promotes tumorigenesis, the over proliferation of tumors, and the overall survival of cancer cells [26]. In certain instances, the continuous activation of JAK 2 has been implicated in the survival, proliferation, angiogenesis, evasion of host immune responses, apoptosis resistance, and metastasis in various human cancers [26,3639]. These findings suggest that drugs targeting the JAK 2/STAT 3 pathway may hold great potential for a new novel therapeutic drug. This study observed hypophosphorylation in JAK 1 and JAK 2, suggesting that F8 inhibits this pathway reducing proliferation and angiogenesis and promoting apoptosis. As was the case for JAK 1 and JAK 2, their downstream effectors STAT 2, STAT 3, and STAT 5 were also found to be hypophosphorylated by F8 treatment. STATs represent a family of crucial transcription factors, driving the progression of cancer through hyperactivation or accumulated mutations that result in gain of function [40].

Excessive activation of STAT3 and STAT5 are implicated in numerous hematopoietic and solid malignancies, including chronic and acute myeloid leukemia, melanoma, and prostate cancer [40]. The heightened activity has been linked to upstream oncogenic triggers, such as the frequently mutated JAK 2 kinase [41]. Interestingly, hyperactive STAT 3 has been associated with large granular T-cell leukemia. Mutated STAT 5 has been identified in patients with T-cell prolymphocytic leukemia, T-ALL, T-cell-derived lymphoma, and monomorphic epitheliotropic intestinal T-cell lymphoma [4244]. Here, we tested the compound F8 on the CCRF-CEM cell line and found reduced STAT 3 and STAT 5 activation. This reduced activation could be implicated in reducing proliferation and may directly induce apoptosis in the CCRF-CEM cell line.

In the near future, the effects of F8 on the phosphorylation of key signaling pathways will be extended to delineate further the critical molecules involved in cell death induction.

Acknowledgments

The authors want to recognize Ms. Gladys Almodovar for the cell culture core. We also thank the Cellular Characterization and Biorepository Core Facility personnel at the Border Biomedical Research Center (BBRC) at the University of Texas at El Paso (UTEP) for their guidance and knowledge.

Data Availability

All relevant data are within the paper.

Funding Statement

This research was funded by the National Institute of General Medical Sciences, under grant number SC3GM088069-03, and the National Cancer Institute, under grant number 5R16GM149379-02, both awarded to RA. Core facilities were supported by the National Institute on Minority Health and Health Disparities (NIMHD) grant 3U54MD007592, awarded to RK. The funders had no involvement in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73: 17–48. doi: 10.3322/caac.21763 [DOI] [PubMed] [Google Scholar]
  • 2.Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17: 93. doi: 10.1038/nrc.2016.138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Marin JJG, Romero MR, Blazquez AG, Herraez E, Keck E, Briz O. Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours. Anticancer Agents Med Chem. 2012;9: 162–184. doi: 10.2174/187152009787313828 [DOI] [PubMed] [Google Scholar]
  • 4.Vanneman M, Dranoff G. Combining Immunotherapy and Targeted Therapies in Cancer Treatment. Nat Rev Cancer. 2012;12: 237. doi: 10.1038/nrc3237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shah R, Verma PK. Therapeutic importance of synthetic thiophene. Chem Cent J. 2018;12: 1–22. doi: 10.1186/S13065-018-0511-5/TABLES/29 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Li Y, Yue K, Li L, Niu J, Liu H, Ma J, et al. A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance. Bioorg Chem. 2020;101: 104011. doi: 10.1016/j.bioorg.2020.104011 [DOI] [PubMed] [Google Scholar]
  • 7.Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6. doi: 10.1038/S41392-021-00572-W [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ruiz-Medina BE, Lerma D, Hwang M, Ross JA, Skouta R, Aguilera RJ, et al. Green barley mitigates cytotoxicity in human lymphocytes undergoing aggressive oxidative stress, via activation of both the Lyn/PI3K/Akt and MAPK/ERK pathways. Sci Rep. 2019;9. doi: 10.1038/s41598-019-42228-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lema C, Varela-Ramirez A, Aguilera RJ. Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds. Curr Cell Biochem. 2011;1(1): 1–14. Available: /pmc/articles/PMC4816492/. [PMC free article] [PubMed] [Google Scholar]
  • 10.Robles-Escajeda E, Das U, Ortega NM, Parra K, Francia G, Dimmock JR, et al. A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cellular Oncology. 2016;39: 265–277. doi: 10.1007/s13402-016-0272-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Robles-Escajeda E, Martínez A, Varela-Ramirez A, Sánchez-Delgado RA, Aguilera RJ. Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells. Cell Biol Toxicol. 2013;29: 431–443. doi: 10.1007/s10565-013-9264-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Santiago-Vázquez Y, Das U, Varela-Ramirez A, T. Baca S, Ayala-Marin Y, Lema C, et al. Tumor-selective Cytotoxicity of a Novel Pentadiene Analogue on Human Leukemia/lymphoma Cells. Clin Cancer Drugs. 2016;3: 138–146. doi: 10.2174/2212697X03666160830165250 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sivandzade F, Bhalerao A, Cucullo L. Analysis of the Mitochondrial Membrane Potential Using the Cationic JC-1 Dyeas a Sensitive Fluorescent Probe. Bio Protoc. 2019;9. doi: 10.21769/BIOPROTOC.3128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Fan X di Zheng HB, Fan XS, Lu S. Increase of SOX9 promotes hepatic ischemia/reperfusion (IR) injury by activating TGF-β1. Biochem Biophys Res Commun. 2018;503: 215–221. doi: 10.1016/J.BBRC.2018.06.005 [DOI] [PubMed] [Google Scholar]
  • 15.Gutierrez DA, DeJesus RE, Contreras L, Rodriguez-Palomares IA, Villanueva PJ, Balderrama KS, et al. A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation. Cell Biol Toxicol. 2019;35: 503–519. doi: 10.1007/s10565-019-09466-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Archives of Toxicology 2013 87:7. 2013;87: 1157–1180. doi: 10.1007/s00204-013-1034-4 [DOI] [PubMed] [Google Scholar]
  • 17.Carboxy-H2DCFDA (general oxidative stress indicator). [cited 25 Sep 2023]. https://www.thermofisher.com/order/catalog/product/C400.
  • 18.Morán-Santibañez K, Vasquez AH, Varela-Ramirez A, Henderson V, Sweeney J, Odero-Marah V, et al. Larrea tridentata extract mitigates oxidative stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. Antioxidants. 2019;8. doi: 10.3390/antiox8100427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.NucView® 488 & RedDot 2 Apoptosis & Necrosis Kit—Biotium. [cited 25 Sep 2023]. https://biotium.com/product/nucview-488-and-reddot-2-apoptosis-necrosis-kit/.
  • 20.Donoso-Bustamante V, Borrego EA, Schiaffino-Bustamante Y, Gutiérrez DA, Millas-Vargas JP, Fuentes-Retamal S, et al. An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells. Bioorg Chem. 2020;100: 103935. doi: 10.1016/j.bioorg.2020.103935 [DOI] [PubMed] [Google Scholar]
  • 21.Robles-Escajeda E, Lerma D, Nyakeriga AM, Ross JA, Kirken RA, Aguilera RJ, et al. Searching in Mother Nature for Anti-Cancer Activity: Anti-Proliferative and Pro-Apoptotic Effect Elicited by Green Barley on Leukemia/Lymphoma Cells. PLoS One. 2013;8: 73508. doi: 10.1371/journal.pone.0073508 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR. Relation between mitochondrial membrane potential and ROS formation. Methods in Molecular Biology. 2012;810: 183–205. doi: 10.1007/978-1-61779-382-0_12 [DOI] [PubMed] [Google Scholar]
  • 23.Torres-Roca JF, Lecoeur H, Amatore C, Gougeon ML. The early intracellular production of a reactive oxygen intermediate mediates apoptosis in dexamethasone-treated thymocytes. Cell Death Differ. 1995;2(4): 309–19. Available: https://pubmed.ncbi.nlm.nih.gov/17180036/. [PubMed] [Google Scholar]
  • 24.Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta Mol Cell Res. 2016;1863: 2977–2992. doi: 10.1016/j.bbamcr.2016.09.012 [DOI] [PubMed] [Google Scholar]
  • 25.Role of caspases in apoptosis | Abcam. [cited 5 Sep 2022]. https://www.abcam.com/kits/role-of-caspases-in-apoptosis.
  • 26.Groner B, von Manstein V. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451: 1–14. doi: 10.1016/J.MCE.2017.05.033 [DOI] [PubMed] [Google Scholar]
  • 27.Hess JD, Macias LH, Gutierrez DA, Moran-Santibanez K, Contreras L, Medina S, et al. Identification of a Unique Cytotoxic Thieno[2,3-c]Pyrazole Derivative with Potent and Selective Anticancer Effects In Vitro. Biology (Basel). 2022;11. doi: 10.3390/biology11060930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Archna, Pathania S, Chawla PA. Thiophene-based derivatives as anticancer agents: An overview on decade’s work. Bioorg Chem. 2020;101: 104026. doi: 10.1016/j.bioorg.2020.104026 [DOI] [PubMed] [Google Scholar]
  • 29.Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17: 395. doi: 10.1038/s41571-020-0341-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006 25:34. 2006;25: 4798–4811. doi: 10.1038/sj.onc.1209608 [DOI] [PubMed] [Google Scholar]
  • 31.Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11: 621–632. doi: 10.1038/nrm2952 [DOI] [PubMed] [Google Scholar]
  • 32.Wu CC, Bratton SB. Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxidants and Redox Signaling. Antioxid Redox Signal; 2013. pp. 546–558. doi: 10.1089/ars.2012.4905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lund T, Stokke T, Olsen E, Fodstad. Garlic arrests MDA-MB-435 cancer cells in mitosis, phosphorylates the proapoptotic BH3-only protein BimEL and induces apoptosis. Br J Cancer. 2005;92: 1773–1781. doi: 10.1038/sj.bjc.6602537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. Programmed Cell Death (Apoptosis). Garland Science; 2002. Available: https://www.ncbi.nlm.nih.gov/books/NBK26873/. [Google Scholar]
  • 35.Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32: 1713. doi: 10.1038/s41375-018-0117-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9: 798. doi: 10.1038/nrc2734 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Harada D, Takigawa N, Kiura K. The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2014;6: 708–722. doi: 10.3390/cancers6020708 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wang H, Wang L, Cao L, Zhang Q, Song Q, Meng Z, et al. Inhibition of autophagy potentiates the anti-metastasis effect of phenethyl isothiocyanate through JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog. 2018;57: 522–535. doi: 10.1002/mc.22777 [DOI] [PubMed] [Google Scholar]
  • 39.Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007;251: 199–210. doi: 10.1016/j.canlet.2006.10.017 [DOI] [PubMed] [Google Scholar]
  • 40.Orlova A, Wagner C, De Araujo ED, Bajusz D, Neubauer HA, Herling M, et al. Direct Targeting Options for STAT3 and STAT5 in Cancer. Cancers (Basel). 2019;11. doi: 10.3390/cancers11121930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Cahu X, Constantinescu SN. Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations. Curr Hematol Malig Rep. 2015;10: 335–343. doi: 10.1007/S11899-015-0278-X [DOI] [PubMed] [Google Scholar]
  • 42.Waldmann TA, Chen J. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. Annu Rev Immunol. 2017;35: 533. doi: 10.1146/annurev-immunol-110416-120628 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018;128: 387. doi: 10.1172/JCI94509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, Von Jan J, et al. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9. doi: 10.1038/s41467-017-02688-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Wagdy Mohamed Eldehna

3 Sep 2023

PONE-D-23-24580Thiophene derivative induces cytotoxicity via the intrinsic apoptotic pathway on human acute lymphoblastic leukemia cellsPLOS ONE

Dear Dr. Aguilera,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 18 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Wagdy Mohamed Eldehna, Ph.d

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://link.springer.com/article/10.1007/s10637-022-01266-y?code=fe9adc41-9b47-40f2-b321-c6ce7bb093af&error=cookies_not_supported

https://www.dovepress.com/getfile.php?fileID=78603

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This work was partially supported by National Institute for General Medical Sciences grants SC3GM088069-03 and 5R16GM149379-02 to RJA.  In addition, partial support was provided by the National Institute of Minority Health and Health Disparities Research Centers at Minority Institutions grant 3U54MD007592). We also thank the Cellular Characterization and Biorepository Core Facility personnel at the Border Biomedical Research Center at the University of Texas at El Paso for their assistance in experimental procedures. "

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"RJA received funding from National Institute for General Medical Sciences grants SC3GM088069-03 and 5R16GM149379-02.  

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

6. Please upload a new copy of Figures 6 and 7 as the detail is not clear. Please follow the link for more information: " ext-link-type="uri" xlink:type="simple">https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" " ext-link-type="uri" xlink:type="simple">https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/"

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript requires revision in order to improve the clarity and coherence of the abstract. Additionally, there is a need to clearly state the aim of the study. Furthermore, grammatical errors should be addressed, particularly in relation to the use of future tense instead of past simple tense.

Compound F8 was recently published as a preclinical candidate for the treatment of undifferentiated gastric cancer. However, the synthesis of compound F8 described in this paper does not correspond to the chemical name you provided. Therefore, we kindly request that you provide us with the purchasing sheet or donation document from ChemBridge DIVERset library for compound F8, including information on its structure, purity, and quantity ordered.

We would also appreciate clarification on what is meant by "said library set" in this context. Did you mean the above-mentioned library?

Additionally, we have a question regarding the dilution protocol used during your experiments for Compound F8, as well as for the positive control and compounds Paclitaxel and Cytochalasin-D.

Furthermore, we would like to inquire about the detection of cell death via the differential nuclear staining (DNS) assay. Specifically, we would like to know if the results were obtained after 48 hours or 96 hours of incubation. It would be helpful if you could attach the raw data from this experiment.

Lastly, we are interested in knowing if there were any in vivo experiments conducted to support your findings.

Moreover, it appears that all figures were not included in the manuscript.

Thank you for your attention to these matters.

Reviewer #2: In this study Swain et al designed and synthesized novel Thiophene derivative induces cytotoxicity via the intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. This work seems interesting, but there are still some important concerns that need to be addressed.

In introduction

1. Authors should provide rational for molecular design linking the main scaffold with the tested molecular target, “MAPK and JAK-STAT” and link to apoptosis induction. A figure should include previously reported compounds with the same moiety. What are the main regions for both proteins that should be targeted?

2. Authors should highlight the novelty of the included work.

In Results

3. Is this compound (F8) novel, or previously reported? If it’s novel, authors should illustrate the synthesis scheme, characterization, and authors should clarify the choice of this compound, specifically for the study?, only one compound for the study may not enough.

4. In the cytotoxicity table, authors should add the IC50 values as “Mean±SD” in one column.

5. What about application of the In silico approaches regarding Docking and ADME pharmacokinetics?

6. Please, indicate which method was used to calculate the CC50 value for cytotoxicity.

7. Regarding DNA fragmentation, authors should provide the original Gel image.

General issues

8. Figures should be introduced in a clearer way with better resolution.

9. Add full definition for all figures captions. All figure legends should be self-explanatory (e.g, the Ic50 value, incubation duration)

10. Please, double check on the plagiarism ratio, grammar issues and typo mistakes.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahmoud Rashed

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Dec 21;18(12):e0295441. doi: 10.1371/journal.pone.0295441.r002

Author response to Decision Letter 0


2 Nov 2023

Reviewer #1:

1. The manuscript requires revision in order to improve the clarity and coherence of the abstract. Additionally, there is a need to clearly state the aim of the study. Furthermore, grammatical errors should be addressed, particularly in relation to the use of future tense instead of past simple tense.

Authors response:

Thank you for pointing this out -we neglected to state the aim from the beginning and did not mention this until the introduction. We have added the following to the beginning of the abstract (lines 23-28) and now feel that it flows much better: In an effort to identify novel anti-cancer agents, we employed a well-established High Throughput Screening (HTS) assay to assess the cytotoxic effect of compounds within the ChemBridge Diverset Library on a lymphoma cell line. This screen revealed a novel thiophene, F8 (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl) amino]-3-thiophenecarboxylate), that displays anti-cancer activity on lymphoma, leukemia, and other cancer cell lines

The overall aim of this study is to investigate the compound F8 as a potential anti-cancer agent. Several assays were conducted to gauge the cytotoxicity of the compound (phosphatidylserine externalization, reactive oxygen species generation, etc). It is stated in the abstract on lines 25-28, "This screen revealed a novel thiophene, F8 (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl) amino]-3-thiophenecarboxylate), that displays anti-cancer activity on lymphoma, leukemia, and other cancer cell lines.” Lines 38-39 state the parameters of our study: "These findings demonstrate that F8 has promising anti-cancer activity."

2. Compound F8 was recently published as a preclinical candidate for the treatment of undifferentiated gastric cancer. However, the synthesis of compound F8 described in this paper does not correspond to the chemical name you provided. Therefore, we kindly request that you provide us with the purchasing sheet or donation document from ChemBridge DIVERset library for compound F8, including information on its structure, purity, and quantity ordered.

Authors response:

In the undifferentiated gastric cancer study, they use a compound with the same name (F8) but our compound has a completely different structure and not at all related. Please refer to the image below and the link to the paper, Development of o-aminobenzamide salt derivatives for improving water solubility and anti-undifferentiated gastric cancer - PMC (nih.gov). The PMID for that paper is 37497111.

The structure of our F8 compound is shown below and can be found at https://www.hit2lead.com/result.asp?search=93458698. Also, please see attached LCMS data of the compound F8. In regards to the purity, it is stated on the Chembridge website, “EXPRESS-Pick™ Stock compounds (7-digit ID compounds): Minimum purity of 90% and identity confirmed using 1H-NMR and/or LC-MS/ELSD.”

3. We would also appreciate clarification on what is meant by "said library set" in this context. Did you mean the above-mentioned library?

Authors response:

As mentioned in the manuscript, "said library set" refers to the ChemBridge DIVERset library where the compound was originally detected.

4. Additionally, we have a question regarding the dilution protocol used during your experiments for Compound F8, as well as for the positive control and compounds Paclitaxel and Cytochalasin-D.

Authors response:

The dilution protocol is stated in the manuscript. In lines 95-99, "The experimental compound was obtained from the ChemBridge DIVERset library and was pre-diluted to 10 mM in dimethyl sulfoxide (DMSO). The compound (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl) amino]-3-thiophenecarboxylate), also known as F8, was found in said library set and used for the experiments detailed below. Aliquots and other concentrations of F8 were thawed and diluted with DMSO. The positive control, H2O2, was alternatively diluted in 1 x phosphate-buffered saline (PBS). Compounds Paclitaxel and Cytochalasin-D were also prepared in DMSO."

5. Furthermore, we would like to inquire about the detection of cell death via the differential nuclear staining (DNS) assay. Specifically, we would like to know if the results were obtained after 48 hours or 96 hours of incubation. It would be helpful if you could attach the raw data from this experiment.

Authors response:

The cell line of interest was plated on day 1 and left overnight (24 h) for the cells to stabilize. The following day, the cells were treated with a range of F8 concentrations and incubated for 24 h to determine the 24 h CC50. The CC50 that were listed in the Table are 48 h concentrations. Please refer to lines 261-262 in the manuscript, stating, "All grown cell lines were incubated at 48 h with F8 to obtain their CC50 value."

6. Lastly, we are interested in knowing if there were any in vivo experiments conducted to support your findings.

Authors response:

There were no in vivo experiments conducted in this study.

7. Moreover, it appears that all figures were not included in the manuscript.

Authors response:

The figure that was mentioned in the text as "data not shown" was a cell cycle using CC50 value obtained after 24 h of incubation. This data was not shown due to the extensive damage to the cells over a 72 h period. We could not properly analyze alterations in the cell cycle without reducing the concentration and that experiment did not fit in the parameters of our study. The sentence indicating data not shown was removed (lines 333-335), as this information does not add or detract from the study.

Reviewer #2:

In this study Swain et al designed and synthesized novel Thiophene derivative induces cytotoxicity via the intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. This work seems interesting, but there are still some important concerns that need to be addressed.

In introduction

1. Authors should provide rational for molecular design linking the main scaffold with the tested molecular target, "MAPK and JAK-STAT" and link to apoptosis induction. A figure should include previously reported compounds with the same moiety. What are the main regions for both proteins that should be targeted?

Authors response:

Please refer to lines 424-426 in the discussion, stating, “This study observed hypophosphorylation in JAK 1 and JAK 2, suggesting that F8 inhibits this pathway, reducing proliferation and angiogenesis and promoting apoptosis." Although we hypothesize a possible role for this pathway, we have no proof for this assertion.

We have attempted many docking experiments in the past with various compounds and found the results unreliable. In other words, we have not found a direct link between a good docking score and actual inhibition of activity. Due to these negative experiences, we do not believe that adding docking experiments will contribute reliable data to the paper and have decided to omit such data. Moreover, at this time, we do not know the principal target enzyme inhibited by the F8 compound and therefore we do not have a target for docking. Once we have more data pointing to a particular pathway or molecule, we will definitely attempt docking experiments.

2. Authors should highlight the novelty of the included work.

In Results?

Authors response:

As mentioned earlier, we neglected to add important information about the main Aim of the project in the Abstract and the Introduction and have amended the MS to reflect this. We have added the following to the beginning of the Abstract (lines 23-28) and now feel that it flows much better: “In an effort to identify novel anti-cancer agents, we employed a well-established High Throughput Screening (HTS) assay to assess the cytotoxic effect of compounds within the ChemBridge Diverset Library on a lymphoma cell line. This screen revealed a novel thiophene, F8 (methyl 5-[(dimethylamino)carbonyl]-4-methyl-2-[(3-phenyl-2-propynoyl) amino]-3-thiophenecarboxylate), that displays anti-cancer activity on lymphoma, leukemia, and other cancer cell lines.”

We have also added the following in the Introduction (lines 51-53):” After screening 1300 compounds, a novel thiophene compound was found to elicit potent cytotoxicity on the Acute Lymphoblastic Leukemia (ALL) CCRF-CEM cell line using the Differential Nuclear Staining (DNS) assay [9].”

3. Is this compound (F8) novel, or previously reported? If it's novel, authors should illustrate the synthesis scheme, characterization, and authors should clarify the choice of this compound, specifically for the study?, only one compound for the study may not enough.

Authors response:

Upon conducting searches of the compound on Pubmed, SciFinder and ChemSpider, we did not find any publications or patents describing the F8 compound, thus indicating it is a novel compound.

4. In the cytotoxicity table, authors should add the IC50 values as "Mean±SD" in one column.

Authors response:

Please refer to line 274 where "Mean±S.D." has been added to Table 1.

5. What about application of the In silico approaches regarding Docking and ADME pharmacokinetics?

Authors response:

The application of in silico docking or ADME pharmacokinetics did not fit in the parameters of our study. We wanted to investigate the compound's potential anti-cancer activity but it is a good suggestion to take into consideration for future studies.

6. Please, indicate which method was used to calculate the CC50 value for cytotoxicity.

Authors response:

It is stated in the manuscript: The cytotoxic concentrations were determined as previously described [9] using a linear interpolator calculator available at (https://www.johndcook.com/interpolator.html). Please refer to lines 125-127.

7. Regarding DNA fragmentation, authors should provide the original Gel image.

Authors response:

Regarding DNA fragmentation, this was conducted by flow cytometry utilizing an assay that measures total DNA content per individual cell. This type of analysis was used for its ability to detect an apoptosis-associated DNA fragmentation pattern at the single-cell level, as manifested by an increase in the sub-G0/G1 cell subpopulation (hypodiploid) during the cell cycle analysis profile. Thus, the DNA fragmentation was not detected on a gel.

General issues

8. Figures should be introduced in a clearer way with better resolution.

Authors response:

The resolution of Figures 6 and 7 has been improved.

9. Add full definition for all figures captions. All figure legends should be self-explanatory (e.g, the Ic50 value, incubation duration).

Authors response:

Please refer to lines 291-294, 304-307, 315-317, 328-330, 343-346, and 374-377 for all the legend figures. Please refer to the example below, highlighting the concentration value and incubation duration.

"Fig 2. F8's induction of apoptosis. F8 compound-induced apoptosis in CEM cells. F8 ability to induce apoptosis was assessed in a phosphatidylserine externalization assay and measured through flow cytometry. Analysis was performed following a 24 h incubation with 24 h CC50 and 2X CC50 (2.89 µM and 5.78 µM). Controls included DMSO as the vehicle, H2O2 as the positive, and untreated. Significant phosphatidylserine externalization was evident for the CC50 and 2X CC50, given the p-value p0.00001 (***)."

10. Please, double check on the plagiarism ratio, grammar issues and typo mistakes.

Authors response:

Please note that significant changes were made in the manuscript in order to avoid plagiarism. Please refer to the document titled “Track changes” to view them. It is also important to take note that similar sentences marked as plagiarism were due to things we cannot change such as our institutional affiliation in addition several sentences in the Materials and Methods are due to techniques we have developed or routinely use in our laboratory and have added the appropriate references of our work.

Attachment

Submitted filename: Response to Reviewers-final.docx

Decision Letter 1

Wagdy Mohamed Eldehna

22 Nov 2023

Thiophene derivative induces cytotoxicity via the intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells

PONE-D-23-24580R1

Dear Dr. Aguilera,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Wagdy Mohamed Eldehna, Ph.d

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed all the requirements, including all comments, figures, and answers to all questions, in a very satisfactory way.

Reviewer #2: Authors addressed all comments, and the manuscript quality was developed accordingly. Some additional comments, authors should check the grammar issues.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahmoud Rashed

Reviewer #2: No

**********

Acceptance letter

Wagdy Mohamed Eldehna

5 Dec 2023

PONE-D-23-24580R1

Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells

Dear Dr. Aguilera:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Wagdy Mohamed Eldehna

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers-final.docx

    Data Availability Statement

    All relevant data are within the paper.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES